MedPHA Bioscience Co., Ltd. is located in the Guangdong–Macao In-Depth Cooperation Zone in Hengqin, Guangdong Province. The company was co-founded by Austrian-educated PhD returnees who bring both distinguished academic backgrounds and extensive industrial experience. The founding shareholders responsible for corporate operations and management possess substantial expertise in management and innovation gained from years of service at multinational corporations. In addition, we have assembled a world-class core technical team of R&D professionals.
MedPHA leverages cutting-edge synthetic biology engineering technologies, with a strong focus on independent innovation. The company is dedicated to the development of next-generation, fully bio-based, naturally biodegradable PHA, as well as the scaled production, application, and commercialization of high-end downstream PHA derivatives. Since 2019, MedPHA has built a comprehensive intellectual property portfolio encompassing patents that cover the entire PHA industrial chain—from microbial strains and fermentation processes to extraction, purification, and application development. Building on this robust IP foundation, the company continues to deepen its R&D capabilities through the establishment of an advanced technology platform for PHA applications.
Guided by its corporate philosophy of "technology first," MedPHA's three core product lines—Industrial-grade PHA, Medical-grade PHA, and the small molecule D3HB—have reached world-leading levels. As fully bio-based materials that are completely biodegradable in all natural environments, PHA products are emerging as revolutionary green materials with enormous market potential, aligning perfectly with the growing global trends toward health-consciousness, microplastic-free living, and low-carbon sustainability. Meanwhile, MedPHA's medical-grade PHA exhibits exceptional biocompatibility and processability, driving its increasing adoption in innovative absorbable medical devices. Developed through the same advanced PHA technology platform via starch–glucose fermentation, D3HB has gained significant popularity among cognitive-intensive users for its unique brain health benefits.
Since its establishment, MedPHA has received a number of prestigious recognitions, including National High-tech Enterprise, Provincial Specialized and New Small and Medium-sized Enterprise, Guangdong Provincial Engineering Research Center for Biosynthesis, Postdoctoral Workstation, Hengqin IPO Reserve Enterprise, and Deloitte China Rising Star. The company has also successfully secured multiple rounds of funding from industrial funds and venture capital firms. Having overcome the severe challenges posed by the pandemic in recent years, MedPHA is now poised to become a global leading supplier of PHA solutions, while actively supporting China's green and health transition and advancing global sustainable development initiatives.
